We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
-1.92%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
-$227M
Cap. Flow
-$69M
Cap. Flow %
-4.99%
Top 10 Hldgs %
65.28%
Holding
52
New
8
Increased
7
Reduced
4
Closed
3

Top Buys

1
RVMD icon
Revolution Medicines
RVMD
+$21M
2
ELVN icon
Enliven Therapeutics
ELVN
+$16.9M
3
BBIO icon
BridgeBio Pharma
BBIO
+$13.7M
4
MGNX icon
MacroGenics
MGNX
+$10.3M
5
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$8.34M

Top Sells

1
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$143M
2
ALLK
Allakos
ALLK
+$23.5M
3
REPL icon
Replimune Group
REPL
+$5.82M
4
KRYS icon
Krystal Biotech
KRYS
+$4.27M
5
EPIX
ESSA Pharma
EPIX
+$1.52M

Sector Composition

1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVI icon
26
Trevi Therapeutics
TRVI
$2.81B
$12.3M 0.89%
6,663,590
– –
MGNX icon
27
MacroGenics
MGNX
$270M
$12.2M 0.88%
+1,703,204
New +$10.3M
REPL icon
28
Replimune Group
REPL
$824M
$12.1M 0.88%
686,762
-244,798
-26% -$5.82M
VECT
29
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$11.6M 0.84%
1,352,199
+18,799
+1% +$155K
CERE
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$9.59M 0.69%
393,000
– –
IMVT icon
31
Immunovant
IMVT
$8.21B
$9.09M 0.66%
585,759
– –
STRO icon
32
Sutro Biopharma
STRO
$395M
$8.21M 0.59%
177,648
– –
MORF
33
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.06M 0.58%
+214,240
New +$7.89M
ARVN icon
34
Arvinas
ARVN
$520M
$7.8M 0.56%
285,331
– –
RNAM
35
DELISTED
Avidity Biosciences
RNAM
$7.67M 0.56%
500,000
– –
NTLA icon
36
Intellia Therapeutics
NTLA
$1.63B
$7.59M 0.55%
203,684
– –
AUTL
37
Autolus Therapeutics
AUTL
$386M
$6.89M 0.5%
3,746,857
– –
JBIO
38
Jade Biosciences
JBIO
$1.28B
$6.82M 0.49%
+9,660
New +$8.01M
PRTA icon
39
Prothena Corp
PRTA
$450M
$6.2M 0.45%
127,900
– –
ZYME icon
40
Zymeworks
ZYME
$1.79B
$5.51M 0.4%
610,000
– –
SLN
41
Silence Therapeutics
SLN
$521M
$5.46M 0.4%
881,173
– –
ALLK
42
DELISTED
Allakos
ALLK
$4.95M 0.36%
1,112,684
-3,679,316
-77% -$23.5M
BLUE
43
DELISTED
bluebird bio
BLUE
$4.58M 0.33%
72,038
– –
EWTX icon
44
Edgewise Therapeutics
EWTX
$4.27B
$4.55M 0.33%
+682,461
New +$6.33M
PASG icon
45
Passage Bio
PASG
$15.3M
$3.6M 0.26%
187,846
– –
ADCT icon
46
ADC Therapeutics
ADCT
$181M
$3.21M 0.23%
+1,647,030
New +$6.08M
ACRS icon
47
Aclaris Therapeutics
ACRS
$764M
$2.14M 0.15%
264,377
-25,812
-9% -$328K
NAMSW icon
48
NewAmsterdam Pharma Warrant
NAMSW
$921K 0.07%
500,333
– –
NBRV
49
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$29.7K ﹤0.01%
17,025
– –
EPIX
50
DELISTED
ESSA Pharma
EPIX
– –
-605,141
Closed -$1.52M
1
2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2023 Portfolio in Review

As of Q1 2023, Frazier Life Sciences Management held 52 positions worth $1.38B, down 14% from $1.61B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Frazier Life Sciences Management withdrew a net $69M in Q1 2023, closing 3 positions and reducing 4 holdings. Its most notable exit was Imago BioSciences, Inc. Common stock, an estimated $143M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Frazier Life Sciences Management opened a new position in Revolution Medicines worth $18.5M.

  • Frazier Life Sciences Management's largest Q1 2023 buy was Revolution Medicines: 854,484 shares worth $18.5M.
  • Frazier Life Sciences Management added most to Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023, an estimated $8.34M increase.
  • Frazier Life Sciences Management's biggest Q1 2023 reduction was Allakos, cutting an estimated $23.5M.
  • Frazier Life Sciences Management fully exited Imago BioSciences, Inc. Common stock in Q1 2023, selling an estimated $143M.
  • Frazier Life Sciences Management's ten largest holdings make up 65% of its $1.38B portfolio in Q1 2023.
  • Frazier Life Sciences Management opened 8 new positions and closed 3 in Q1 2023.
  • Frazier Life Sciences Management's portfolio value fell 14% quarter-over-quarter to $1.38B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2023, filed 15 May 2023.